Hospira Expands Recall of Propofol and Liposyn

Hospira is voluntarily expanding its recall of its Propofol Injectable Emulsion 1% and Liposyn products, including Liposyn II 10%, Liposyn II 20%, Liposyn III 10%, Liposyn III 20% and Liposyn III 30%, due to particulate matter found in some of the containers, according to an alert from the U.S. Food and Drug Administration.

Advertisement

Staff

The affected lot numbers are:

  • Propofol — lot numbers beginning with 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 82, 83, 84 and 85.   
  • Liposyn — lot numbers beginning with 72, 73, 74, 75, 76, 77, 78, 82, 83, 84 and 85.

The affected lots of propofol were distributed between March 2008 and April 2010. The affected lots of Liposyn were distributed between Dec. 2008 and April 2010.

Read the FDA’s alert about the Hospira recall.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.